First Quarter 2021

Corporate update and financial results

May 10, 2021
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including BioNTech's efforts to combat COVID-19; the collaboration between BioNTech and Pfizer regarding a COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our continuing trials and/or in commercial use based on data observations to date, including real-world data gathered; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on trial data of BNT162b2 in our ongoing trials; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates and targets for 2021 and 2022; BioNTech's projected revenues for the COVID-19 vaccine in 2021; BioNTech's projected expenses, capital expenditures and tax rate for 2021; BioNTech's target vaccine production for 2021; BioNTech's COVID-19 vaccine revenues and net sales, which are subject to numerous estimates as more fully described in our Annual Report on Form 20-F and our Quarterly Report for the Three Months ended March 31, 2021; the planned next steps in BioNTech's pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of BioNTech's product candidates; BioNTech's plans for expansion in South East Asia, including its planned regional headquarters and manufacturing facility in Singapore; and expectations for data announcements with respect to BioNTech's clinical trials. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this quarterly report are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in this quarterly report and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this quarterly report in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof.
AUTHORIZED USE IN THE U.S.:
The Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.

IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION:
- Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.
- Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine.
- Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/).
- Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.
- The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.
- In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%).
- Severe allergic reactions, including anaphylaxis, have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials.
- Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 Vaccine.
- Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.
- Data are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion.
- There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series.
- Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The reports should include the words "Pfizer-BioNTech COVID-19 Vaccine EUA" in the description section of the report.
- Vaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization.

First Quarter 2021 Highlights
COVID-19 Vaccine Update
Oncology Pipeline Update
Financial Results
Corporate Update & Outlook
Transformed into a Fully Integrated, Global Immunotherapy Company

Fully Integrated Structure

- Deep Immunology Expertise
- Broad Suite of Novel Technologies
- Bioinformatics Approach
- In-House Manufacturing
- Commercial Capabilities
- Global Team of 2,000+

A Robust Pipeline of 20+ Candidates

Next-Gen Immunotherapies & Vaccines
Oncology, Infectious Disease and Beyond

Potential to Launch Multiple Products in Next 5 Years

Accelerated by Proven Execution and COVID-19 Vaccine Cash Flow
Building a 21st Century Global Immunotherapy Powerhouse

**Increase global footprint**
- New regional headquarters planned in Singapore
- Commercial subsidiaries established in Germany and Turkey
- Offices established in the United States

**Expand integrated infrastructure**
- Continue investment in innovation to support future product launches
- Invest in clinical, commercial and manufacturing, and digital capabilities
- Attract and retain top talent

**Rapidly advance pipeline**
- 14 product candidates in 15 ongoing clinical trials
- 3 potentially registrational phase 2 trials initiating this year
- Advance innovations into first-in-human studies
- Strategic in-licensing to complement internal R&D
Highlights From First Quarter 2021 and Beyond

First Patients Dosed in Multiple First-in-Human Studies

- Next generation CAR-T in combination with CARVac (BNT211)
- NEO-STIM Neoantigen-targeting T cell therapy (BNT221)
- Ribocytokine (BNT151)

Executational Excellence in Infectious Disease with COVID-19 Vaccine

- >450M doses shipped to 91 countries and territories worldwide*
- ~1.8 billion doses contracted to date for 2021, and with first contracts in place for 2022 and beyond
- €2.0 billion COVID-19 vaccine revenues in Q1
- Topline results confirming high efficacy and no serious safety concerns through up to six months following second dose
- 100% efficacy and robust antibody responses in Phase 3 trial of adolescents aged 12-15

*as of May 6
In March 2021, BioNTech announced its Full Year 2020 Financial Results and Corporate Update as a part of the Annual Report filed in Form 20-F, highlighting developments relating to its COVID-19 vaccine program between January 1 and March 30, 2021. This slide focuses on developments that occurred after March 30, 2021.
Focused on Six Key Levers to Expand COVID-19 Vaccine Reach

**Increased Manufacturing Capacity**
- Up to 3 billion doses by end of 2021; more than 3 billion doses in 2022
- First shipments from Marburg facility delivered mid April
- New regional headquarters in Singapore to house mRNA manufacturing facility

**Additional Populations**
- Expect FDA feedback on EUA label expansion in adolescents 12 to 15 years in May
- Variation submitted to EMA to expand label in adolescents 12 to 15 years
- Ongoing study in children 6 months to 11 years of age; first data expected in Q3

**Additional Geographies**
- Authorized or approved for emergency authorization in more than 70 countries worldwide
- Shipped to 91 counties and territories
- Regulatory submission for BLA in China underway

**Broadened & Decentralized Vaccine Access**
- U.S. rolling BLA submission initiated
- Initiated Phase 3 trial to evaluate lyophilized and a ready-to-use formulation; data expected in Q3
- Data submitted to FDA and EMA to broaden label to 4-week storage at 2°C to 8°C

**Addressing SARS-CoV-2 Variants**
- Ongoing trial to evaluate variant-specific version BNT162b2SA in naïve and vaccinated individuals as well as third dose of BNT162b2 at 6 – 12 months post dose 2
  - Effect on waning immune response against original strain
  - Effect on immune response against variant strains

**Addressing Waning Immune Responses**
- Authorized or approved for emergency authorization in more than 70 countries worldwide
- Shipped to 91 counties and territories
- Regulatory submission for BLA in China underway

---

In March 2021, BioNTech announced its Full Year 2020 Financial Results and Corporate Update as a part of the Annual Report filed in Form 20-F, highlighting developments relating to its COVID-19 vaccine program between January 1 and March 30, 2021. This slide focuses on developments that occurred after March 30, 2021.
Preemptive Strategy to be Prepared for Addressing SARS-CoV-2 Variants

- No evidence that adaptation of BNT162b2 is needed to date
  - Sera of BNT162b2 vaccinated individuals neutralize B.1.1.7 (UK), B.1.351 (SA), and P.1 (brazilian) lineage* in *in vitro* studies

- Expansion of global Phase 1/2/3 trials:
  - 3rd dose to evaluate safety, magnitude and duration of immunity and variant protection
  - Variant specific booster to evaluate safety and immunogenicity of B.1.351 Spike version of BNT162b2 (BNT162b2\textsubscript{SA})
  - “Blueprint“ approach informs regulatory path and manufacturing

<table>
<thead>
<tr>
<th>Prime</th>
<th>1st Boost</th>
<th>2nd Boost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1 participants</td>
<td>Dose 1 BNT162b2</td>
<td>Dose 2 BNT162b2</td>
</tr>
<tr>
<td>Phase 3 participants</td>
<td>Dose 1 BNT162b2</td>
<td>Dose 2 BNT162b2</td>
</tr>
<tr>
<td>Newly enrolled naïve adults n=300</td>
<td>Dose 1 BNT162b2\textsubscript{SA}</td>
<td>Dose 2 BNT162b2\textsubscript{SA}</td>
</tr>
</tbody>
</table>

*Boostability of BNT162b2*  

*Booster trial with BNT162b2 or BNT162b2\textsubscript{SA}*  

- No evidence that adaptation of BNT162b2 is needed to date
  - Sera of BNT162b2 vaccinated individuals neutralize B.1.1.7 (UK), B.1.351 (SA), and P.1 (brazilian) lineage* in *in vitro* studies

| Dose 4 BNT162b2\textsubscript{SA} |

*8. B.1.17 (UK variant), B.1.351 (South African variant), and P.1 lineage (Brazilian variant)  
Liu et al., NEJM, Mar. 8, 2021*
Strong Order Book Growth in Q1

~1.8 billion doses contracted for 2021

<table>
<thead>
<tr>
<th>Selected Regions</th>
<th>Current Orders 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU</td>
<td>600 million</td>
</tr>
<tr>
<td>US</td>
<td>300 million</td>
</tr>
<tr>
<td>Japan</td>
<td>144 million</td>
</tr>
<tr>
<td>UK</td>
<td>90 million</td>
</tr>
<tr>
<td>Other</td>
<td>~680 million</td>
</tr>
</tbody>
</table>

First orders contracted for 2022 and beyond
125 million doses for Canada in 2022/2023 with option for 60 million in 2024
Millions of doses to be supplied to Israel in 2022
Ongoing discussions in other regions for additional doses in 2021 and beyond

Expanding vaccine access to new populations & geographies with first supply contracts for post-2021
Manufacturing Capacity Increased to Address Worldwide Vaccine Need

- BioNTech now targeting 3 billion doses in 2021*
- Manufacturing capacity in 2022 to exceed 3 billion doses

- BioNTech contributing more than 50% of drug substance
- **Marburg site launch brings BioNTech manufacturing capacity to 1 billion doses annually**
  - BioNTech expects to deliver ~250 million doses in 1H 2021
  - Marburg site first batch delivered in April
  - Established mRNA manufacturing in Marburg facility in less than six months
  - To become one of the largest mRNA manufacturing sites worldwide

*This assumes continuous process improvements and expansion at our current facilities and contingent upon adding more suppliers and contract manufacturers.
## Agenda

<table>
<thead>
<tr>
<th>First Quarter 2021 Highlights</th>
<th>COVID-19 Vaccine Update</th>
<th><strong>Oncology Pipeline Update</strong></th>
<th>Financial Results</th>
<th>Corporate Update &amp; Outlook</th>
</tr>
</thead>
</table>

**COVID-19 Vaccine Update**

**Oncology Pipeline Update**

**Financial Results**

**Corporate Update & Outlook**
Tackling Multiple Diseases with Different Therapeutic Modalities

**mRNA Cancer Vaccines**

- iNeST and FixVac
  - Multi-specificity, multi-valency, high (neo)antigen specific T cell responses with unprecedented potency
  - Ongoing Phase 2 randomized trial (iNeST)

- CARVac: Paired with mRNA vaccination to enhance PK and persistence
  - Phase 1 FIH trials started in Feb. and Apr.

**Next Generation Immunomodulators**

- Bispecifics
  - Next-generation checkpoint inhibitors to address a broad range of cancers
  - Ongoing Phase 1/2 trials of 2 bi-specific antibodies

**Cell Therapies**

- Next Gen CAR-T Cell Therapy
  - Neoantigen-based T Cell Therapy

- Targeted Cancer Antibodies
  - CA19-9 antibody in 1L pancreatic cancer
  - Ongoing Phase 1/2 trial

- Small Molecule Immunomodulators
  - Potently modulates innate immunity
  - Potential for combination with other IO agents
  - Ongoing Phase 1 trial

- Ribocytokines
  - mRNA encoded cytokines with a prolonged T1/2 and improved safety profile
  - Amplify vaccines and CPIs
  - Phase 1 FIH trial started in Feb.

**Engineered Cytokines**

- Multiple blockbuster opportunities with synergistic combinations

PK, Pharmacokinetics; CA 19-9: Cancer antigen 19-9; IO, Immuno-oncology; CPI, Check-point Inhibitor
### Multiple Oncology Trials with Registrational Potential Starting in 2021

#### Plan to start randomized Phase 2 trials for 3 programs

#### Advanced Oncology Pipeline Programs

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Platform</th>
<th>Product Candidate</th>
<th>Indication (Targets)</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA</td>
<td>FixVac (fixed combination of shared cancer antigens)</td>
<td>BNT111</td>
<td>advanced melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BNT113</td>
<td>HPV16+ head and neck cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>iNeST (patient specific cancer antigen therapy)</td>
<td>autogene cevumeran (BNT122)</td>
<td>BNT113</td>
<td>1L melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adjuvant colorectal cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibodies</td>
<td>Next-Gen Checkpoint Immunomodulators</td>
<td>GEN1046 (BNT311)</td>
<td>solid tumors (PD-L1×4-1BB)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GEN1042 (BNT312)</td>
<td>solid tumors (CD40×4-1BB)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Near-Term Milestones

- **BNT111**: Phase 2 to start in 1H 2021
- **BNT113**: Phase 2 to start in 1H 2021
- **BNT122**: Phase 2 to start in 2H 2021 (adjuvant CRC)
- **BNT311**: Data update in 2H 2021
- **BNT312**: Data update in 2H 2021
Next Wave Oncology Advancing Innovation Beyond Current Boundaries

**CARVac**
CAR-T cell amplifying mRNA therapy for solid tumors

- BNT211 (CLDN 6 CAR)
  Next generation CAR-T targeting CLDN6 with CARVac

**NEOSTIM T cell therapy**
Individualized Neoantigen specific T cell therapy

- BNT221
  PBMC derived ex vivo T cell therapy

**RiboCytokines**
mRNA encoded Cytokines

- BNT151
  (modified IL-2)
  - BNT152 + BNT153
    (IL-2/IL-7)

**RiboMabs²**
mRNA encoded Antibodies

- BNT141
  (undisclosed)
  - BNT142
    (CD3xCLDN6)

---

FPD, first patient dosed; CLDN6, Claudin-6, CAR-T cells, chimeric antigen receptor T cells; IL-2, interleukin 2; IL-7, Interleukin 7; PBMC, peripheral blood mononuclear cells; FIH, first in human

**BNT111: FixVac Melanoma Compelling Preliminary Data**

**Off-the-shelf mRNA Immunotherapy**
- Fixed combination of non-nucleoside modified mRNA
- Encodes 4 tumor-associated antigens (TAA) covering ~95% of melanoma patients
- Intravenous formulation targets antigen presenting cells bodywide to stimulate antigen-specific T cell responses

**Phase 1 trial in Advanced Melanoma published in Nature**
- Tolerable safety as monotherapy and in combination with CPI
- Durable Objective Responses in CPI-experienced patients with evaluable disease at baseline
  - ORR 35% for combination therapy (BNT111 + anti-PD1): 6/17 patients
- High-magnitude and persistent CD4+ and CD8+ T cell responses

**An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma**

**TPTE**, trans-membrane phosphatase with tensin homology; **SP**, surfactant protein; **UTR**, untranslated region; **MITD**, MHC I-targeting domain; **PD1**, programmed death-ligand 1; **CPI**, checkpoint inhibitor; **ORR**, overall response rate

https://www.nature.com/articles/s41586-020-2537-9
BNT111: FixVac Phase 2 Clinical Trial in anti-PD1 R/R Melanoma Patients

**Open-label, randomized Phase 2 trial with BNT111 and cemiplimab in combination or as single agents**

- Collaboration with Regeneron

**Primary EP**
- Arm 1: ORR by RECIST 1.1

**Secondary EP**
- ORR (key secondary endpoint arms 2, 3)
- DOR, DCR, TTR, PFS, by RECIST 1.1
- OS, safety, tolerability, PRO

- Patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma

- BNT111-01

- BNT111 + cemiplimab up to 24 months
  - n=60
  - Addition of cemiplimab upon disease progression

- BNT111 up to 24 months
  - n=30
  - Addition of BNT111 upon disease progression

- Cemiplimab up to 24 months
  - n=30

- OS Follow-up every 3 months for 48+ months from first dose

- 2:1:1 n=120

- **BNT111**

- **cemiplimab**

- **up to 24 months**

- **Addition of cemiplimab upon disease progression**

- **Addition of BNT111 upon disease progression**

- **n=30**

- **n=30**

- **n=60**

- **PD1, programmed death-ligand 1; EP, endpoint; ORR, overall response rate; DOR, duration of response; DCR, disease control rate; TTR, time to response; PFS, progression free survival; OS, overall survival; PR, patient reported outcomes; R/R, refractory, relapsed**

- https://clinicaltrials.gov/ct2/show/record/NCT04526899
**BNT211: Next Generation CAR-T Targeting CLDN6 with CARVac**

**BNT211 CAR Structure**

- αCLDN6 scFv
- CD8 hinge
- 4-1BB
- CD3ζ

**CLDN6 not present in healthy tissues**

**CLDN6 expressed in multiple cancers**

- Ovarian
- Testicular
- Lung

---

**CAR-T cell therapy + RNA Vaccine to amplify CAR-T cell *in vivo***

- New 2nd generation CAR directed against CLDN6, a new highly cancer cell specific carcino-embryonic antigen
- CLDN6 is expressed in multiple solid cancers with high medical need tumor types
- CARVac drives in vivo expansion, persistence and efficacy of CAR-T

---

**Science**


---

CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment; Reinhard K, et al. Science 2020; 367:446-453
An open-label Phase 1/2a study of BNT211 in patients with advanced solid tumors

- Evaluation of safety and tolerability
- Ongoing Phase 1/2a study
- Monotherapy dose level 1 completed (3 patients)
BNT211: CAR-T Engraftment and Stable Disease in First 2 Patients

<table>
<thead>
<tr>
<th>Patient #</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, gender</td>
<td>68 y, female</td>
<td>25 y, male</td>
<td>33 y, male</td>
</tr>
<tr>
<td>Tumor entity</td>
<td>Ovarian CA</td>
<td>Sarcoma</td>
<td>Testicular CA</td>
</tr>
<tr>
<td>CLDN6 II/III+</td>
<td>60%</td>
<td>80%</td>
<td>60%</td>
</tr>
<tr>
<td>Stage</td>
<td>FIGO IIIc</td>
<td>unknown</td>
<td>IIIc</td>
</tr>
<tr>
<td>Prior treatment lines</td>
<td>5</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>CAR-T infusion</td>
<td>FEB2021</td>
<td>MAR2021</td>
<td>MAR2021</td>
</tr>
<tr>
<td>DLTs</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AEs ≥ grade 3*</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CAR-T engraftment</td>
<td>9x (days 3-17)</td>
<td>&gt;700x (days 3-24)</td>
<td>90x (days 3-10)</td>
</tr>
</tbody>
</table>

First dose level was well tolerated
- AEs Mild to Moderate & Transient
- No AEs ≥ grade 3 and no DLTs

CAR-T detectable across different tumor types
- Robust engraftment in all patients,
  - Follow-up days 3-24 for patient #1 and #2, and days 3-10 for patient #3 post CAR-T cell transfer

Tumor Reduction in Patient #2:
- 19.7% shrinkage of tumor (RECIST 1.1)

DLT, dose limiting toxicity; Pat, patient; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease;
LD, lymphodepletion; FIGO, International Federation of Gynecology and Obstetrics; CLDN6, Claudin-6; AE, adverse event; CAR-T, chimeric antigen receptor engineered T cells
* Suspected to be related to drug product
BNT221: NEO-STIM® Personalized Neoantigen-Targeted Adoptive Cell Therapy

Addresses limitations of TIL cell therapy approaches

• T cells induced from peripheral blood (NEO-STIM)
  • No gene engineering or viral vectors
  • Targets each patient’s personal tumor neoantigens
  • Multiple specific CD8+ and CD4+ T cell populations that are functional and have a favorable phenotype
• First patient dosed in Phase 1 trial in anti-PD-1 experienced unresectable stage III or IV melanoma

BNT221 cells specifically recognize autologous tumor

Cytokine response: IFN-γ+ and/or CD107a+ (of CD8+pMHC+)

First Quarter 2021 Financial Results (unaudited) – Profit or Loss

### (in millions, except per share data)*

<table>
<thead>
<tr>
<th></th>
<th>Three months ended March 31</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021</td>
</tr>
<tr>
<td>Research &amp; development revenues</td>
<td>€20.9</td>
</tr>
<tr>
<td>Commercial revenues</td>
<td>2,027.5</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td><strong>€2,048.4</strong></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(233.1)</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>(216.2)</td>
</tr>
<tr>
<td>Sales and marketing expenses</td>
<td>(8.7)</td>
</tr>
<tr>
<td>General and administrative expenses</td>
<td>(38.9)</td>
</tr>
<tr>
<td>Other operating income less expenses</td>
<td>110.7</td>
</tr>
<tr>
<td><strong>Operating profit / (loss)</strong></td>
<td><strong>€1,662.2</strong></td>
</tr>
<tr>
<td>Finance income less expenses</td>
<td>(19.9)</td>
</tr>
<tr>
<td>Income taxes</td>
<td>(514.2)</td>
</tr>
<tr>
<td><strong>Profit / (loss) for the period</strong></td>
<td><strong>€1,128.1</strong></td>
</tr>
</tbody>
</table>

### Earnings per share

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic profit / (loss) for the period per share</td>
<td>€4.64</td>
<td>€(0.24)</td>
</tr>
<tr>
<td>Diluted profit / (loss) for the period per share</td>
<td>€4.39</td>
<td>€(0.24)</td>
</tr>
</tbody>
</table>

*Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the interim consolidated statements of profit or loss has been condensed.
First Quarter 2021 COVID-19 Vaccine Deliveries Drove Revenue Growth

Commercial revenues – identified revenue streams

- Share of gross profit from COVID-19 vaccine sales in the Pfizer territory (net position) and sales milestones*
- Direct COVID-19 vaccine sales to customers in BioNTech territory
- Sales to collaboration partners of products manufactured by BioNTech
- Other sales (mainly JPT and IMFS business)

*Represents an estimated figure based on preliminary data shared between Pfizer and BioNTech. Changes in share of the collaboration partner's gross profit will be recognized prospectively.
On Track with Previously Stated Financial Outlook

Update on Current Signed COVID-19 Vaccine Order Book

• Estimated COVID-19 vaccine revenues to BioNTech upon delivery of signed supply contracts as of May 4, 2021 (~1.8 billion doses): ~€12.4 billion

Planned Full Year 2021 Expenses and Capex

• R&D expenses: €750 million – €850 million
• SG&A expenses: Up to €200 million
• Capital expenditures: €175 million – €225 million
• Ranges reflect current base case projections
• Ramp-up of R&D investment in 2H 2021 and beyond planned to broaden and accelerate pipeline development

Estimated Full Year 2021 Tax Assumptions

• German corporate tax rate: ~31%
Agenda

- First Quarter 2021 Highlights
- COVID-19 Vaccine Update
- Oncology Pipeline Update
- Financial Results
- Corporate Update & Outlook
Increasing Our Global Footprint

• First location in Asia: regional headquarters in Singapore to house mRNA manufacturing facility with support from Singapore Economic Development Board

• Growing international workforce with teams in United States, an affiliate in Turkey and commercial organization, including salesforce, in Germany
Significant Pipeline Milestones expected in 2021

5+ Trial Updates

- **BNT162b2**: Multiple updates
- **BNT311**: Bi-specific CPI: PD-L1 x 4-1bb in solid tumors
- **BNT312**: Bi-specific checkpoint immunomodulator CD40 x 4-1bb in solid tumors
- **BNT211**: CLDN-6 CAR-T + CARVac in solid tumors
- **BNT411**: TLR-7 agonist +/- CPI in solid tumors

3 Randomized Phase 2 Trial Starts

- **BNT111**: FixVac + CPI in refractory melanoma
- **BNT113**: FixVac HPV16+ + CPI in 1L HNSCC
- **BNT122**: iNeST (autogene cevumeran) + CPI in adjuvant mCRC

7 First-in-human Phase 1 Trial Starts

- **BNT211**: CLDN-6 CAR-T + CARVac in solid tumors
- **BNT151**: Ribocytokine (modified IL-2)
- **BNT221**: NEOSTIM individualized neoantigen-T cell therapy in melanoma
  - **BNT152+153**: RiboCytokine IL-2 / IL-7 combo in solid tumors
  - **BNT141**: RiboMab (undisclosed)
  - **BNT142**: RiboMab bi-specific CPI in solid tumors (CD3xCLDN6)
  - **BNT161**: Influenza vaccine
Strong Financial Position, Fully-Integrated Structure Enable Execution on Strategic Priorities for 2021

Vaccine revenue provides significant working capital to build long-term value for patients, shareholders and society

• Continue to execute while driving iterative innovation against COVID-19
  • Deliver COVID-19 vaccine to >1 billion people globally

• Broaden and diversify early- and late-stage pipeline of next generation immunotherapies
  • Accelerate pipeline in core therapeutic areas
    • Immuno-oncology: Usher in new era of individualized cancer medicine and *in vivo* cell therapy
    • Infectious disease: Advance mRNA vaccines and therapeutics to address infectious diseases beyond COVID-19
  • Further optimize platforms and initiate early product development in emerging areas
  • Increase global footprint and expand integrated infrastructure
An der Goldgrube 12
55131 Mainz
Germany

M: investors@biontech.de